Literature DB >> 11147933

Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.

R Ramasubbu1, A Ravindran, Y Lapierre.   

Abstract

BACKGROUND: Previous reports suggest that some atypical antipsychotics may have obsessogenic as well as antiobsessional effects. Given their higher affinity for serotonin 5HT2 receptors than dopamine D2 receptors, it has been speculated that atypical antipsychotics may induce obsessive-compulsive (OC) symptoms, even at low doses, due to high 5HT2 antagonism, whereas improvement in OC symptoms is thought to occur only at high doses due to high D2 antagonism.
METHOD: In this open case series, the dose-response relationship of atypical antipsychotic augmentation in the treatment of obsessive compulsive disorder (OCD), and the dose-severity relationship in atypical anti psychotic-induced OC symptoms were examined. Three patients were identified who had either refractory OCD or OC symptoms following administration of atypical antipsychotics such as olanzapine and risperidone.
RESULTS: Case 1: A linear dose-response relationship between increasing doses of olanzapine and improvement in OC symptoms was observed in an OCD patient resistant to 5-HT reuptake inhibitors. 2: OC symptoms induced by low doses of risperidone (1 mg) were reversed by increasing the doses of risperidone (3 mg) in a bipolar disorder patient suggesting an inverse dose-severity relationship. 3: No inverse dose-severity relationship was noted between olanzapine induced OC symptoms and its dosage in an asymptomatic OCD patient. Tretment-emergence OC symptoms responded to increasing the doses of maintanance clomipramine treatment.
CONCLUSIONS: Controlled studies are needed to investigate the dose-response or dose-severity relationships between OCD and atypical antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11147933     DOI: 10.1055/s-2000-8360

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  9 in total

1.  Drug Induced Obsessive Compulsive Disorder in Schizophrenia.

Authors:  R K Saini; V Pande
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  Comorbidity in Schizophrenia: Conceptual Issues and Clinical Management.

Authors:  Hussain Muhammad Abdullah; Hameed Azeb Shahul; Michael Y Hwang; Stephen Ferrando
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

3.  The 5-HT7 receptor influences stereotypic behavior in a model of obsessive-compulsive disorder.

Authors:  Peter B Hedlund; J Gregor Sutcliffe
Journal:  Neurosci Lett       Date:  2007-01-11       Impact factor: 3.046

Review 4.  Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment.

Authors:  Michael Poyurovsky; Abraham Weizman; Ronit Weizman
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 5.  Obsessive-Compulsive Symptoms in Schizophrenia: an Up-To-Date Review of Literature.

Authors:  Chloé Tezenas du Montcel; Antoine Pelissolo; Franck Schürhoff; Baptiste Pignon
Journal:  Curr Psychiatry Rep       Date:  2019-07-01       Impact factor: 5.285

Review 6.  Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence.

Authors:  Chi-Un Pae; Alessandro Serretti; Ashwin A Patkar; Praksh S Masand
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  Obsessive-compulsive disorder with bipolar diathesis following isotretinoin therapy remitting upon treatment with olanzapine and fluvoxamine.

Authors:  Michele Fornaro
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-29       Impact factor: 2.570

8.  Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.

Authors:  Neda Askari; Mahdieh Moin; Mohammad Sanati; Masih Tajdini; Seyed-Mohammad-Reza Hosseini; Amirhossein Modabbernia; Babak Najand; Samrand Salimi; Mina Tabrizi; Mandana Ashrafi; Reza Hajiaghaee; Shahin Akhondzadeh
Journal:  CNS Drugs       Date:  2012-10-01       Impact factor: 6.497

Review 9.  Critical Review of the Use of Second-Generation Antipsychotics in Obsessive-Compulsive and Related Disorders.

Authors:  Dongmi Kim; Nicole L Ryba; Julie Kalabalik; Ligia Westrich
Journal:  Drugs R D       Date:  2018-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.